CSIR-CCMB and Aurobindo Pharma Ltd have entered into a collaboration for developing a COVID-19 vaccine against SARS-CoV-2. As a part of the collaboration CSIR labs (CSIR-CCMB, CSIR-IICB and CSIR-IMTECH) shall make available the SARS-COV-2 candidate proteins/complexes for vaccine development after pre-clinical success to Aurobindo. CSIR Labs shall conduct the non-GMP preclinical studies and then transfer/license the technology at the Proof-of-Concept stage to Aurobindo Pharma. Aurbindo will carry out GMP compliant large-scale production and development of the vaccine. Aurobindo shall scale up the vaccine production and initiate Phase I trials.